Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.
Mulligan MJ, Bernstein DI, Frey S, Winokur P, Rouphael N, Dickey M, Edupuganti S, Spearman P, Anderson E, Graham I, Noah DL, Mangal B, Kim S, Hill H, Whitaker J, Emery W, Beck A, Stephens K, Hartwell B, Ogilvie M, Rimann N, Osinski E, Destefano E, Gajadhar T, Strudwick A, Pierce K, Lai L, Yue L, Wang D, Ying C, Cline A, Foltz T, Wagner N, Dull G, Pacatte T, Taggart B, Johnson V, Haller L, Looney C, Li S, May M, Myers B, May R, Parker L, Cochran N, Bowen D, Bell M, Scoggins J, Burns A, Stablein C, Wolff M, Jolles B, Leung B, Lambert L, Shorer S, Buchanan W, Murray S, Chang S, Gorman R.
Mulligan MJ, et al. Among authors: hartwell b.
Open Forum Infect Dis. 2014 Nov 18;1(3):ofu102. doi: 10.1093/ofid/ofu102. eCollection 2014 Dec.
Open Forum Infect Dis. 2014.
PMID: 25734170
Free PMC article.